21We assessed the utility of genome sequencing for early-onset dementia. Participants were selected 22 from a memory disorders clinic. Genome sequencing was performed along with C9orf72 repeat 23 expansion testing. All returned sequencing results were Sanger validated clinically. Prior clinical 24 diagnoses included Alzheimer's disease, frontotemporal dementia, and unspecified dementia. The 25 mean age-of-onset was 54 (41-76). 50% of patients had a strong family history, 37.5% had some, and 26 12.5% had no known family history. Nine of 32 patients (28%) had a variant defined as pathogenic or 27 likely pathogenic (P/LP) by American College of Medical Genetics standards, including variants in APP, 28 C9orf72, CSF1R, and MAPT. Nine patients (including three with P/LP variants) harbored established 29 risk alleles with moderate penetrance (odds ratios of about 2-5) in ABCA7, AKAP9, GBA, PLD3,